In his weekly clinical update, Dr. Griffin discusses the immunogenicity and reactogenicity of coadministration of COVID-19 and Influenza vaccines, interim effectiveness estimates of 2023 southern hemisphere influenza vaccines in preventing Influenza-associated hospitalizations, genome-wide association study of susceptibility to RSV hospitalization in young children <5 years of age, performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection, safety and immunogenicity of XBB.1.5-containing mRNA vaccines, optimal duration of systemic corticosteroids in COVID-19 treatment, timing and predictors of loss of infectivity among healthcare workers with mild primary and recurrent COVID-19, and effects of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Immunogenicity and reactogenicity of coadministration of COVID-19 and Influenza vaccines (JAMA) Effectiveness estimates of Influenza vaccines in preventing associated hospitalizations (CDC) Genome-wide association study of susceptibility to RSV hospitalization in children (JID) Performance of rapid antigen tests to detect SARS-CoV-2 infection (AIN) Safety and immunogenicity of XBB.1.5-containing mRNA vaccines (medRxiv) C.D.C. director explains why you should get the latest Covid booster (Nytimes) Optimal duration of systemic corticosteroids in COVID-19 treatment (OFID) Timing and predictors of loss of infectivity among healthcare workers with COVID-19 (CID) Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection (JPR) Contribute to our Floating Doctors fundraiser at PWB Letters read on TWiV 1044 Dr. Griffin’s COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv